Non-alcoholic Fatty Liver Diseases (NAFLD) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice
In this study, after 12 weeks of induction, the mice were treated with emodin succinyl ethyl ester (ESEE) for four weeks at doses of 10/30/90 mg/kg/day. The blood analysis of experimental endpoints showed that ESEE exhibited significant therapeutic effects on the progression of disorders of glycolipid metabolism and the induced liver injury in the model animals. Histopathological diagnosis of the liver and total triglyceride measurements revealed that ESEE had a significant therapeutic effect on the histopathological features of nonalcoholic fatty liver disease/hepatitis, such as cellular steatosis and activation of intrah...
Source: Biological and Pharmaceutical Bulletin - April 17, 2024 Category: Drugs & Pharmacology Authors: Yanxue Wang Liang Li Lingling Chen Jinlei Xia Tongli Wang Lei Han Liang Cao Zhenzhong Wang Wei Xiao Shan Jiang Source Type: research

Triclocarban induces lipid droplet accumulation and oxidative stress responses by inhibiting mitochondrial fatty acid oxidation in HepaRG cells
Toxicol Lett. 2024 Apr 15;396:11-18. doi: 10.1016/j.toxlet.2024.04.002. Online ahead of print.ABSTRACTMitochondrial fatty acid oxidation (mtFAO) plays an important role in hepatic energy metabolism. Severe mtFAO injury leads to nonalcoholic fatty liver disease (NAFLD) and liver failure. Several drugs have been withdrawn owing to safety issues, such as induction of fatty liver disease through mtFAO disruption. For instance, the antimicrobial triclocarban (TCC), an environmental contaminant that was removed from the market due to its unknown safety in humans, induces NAFLD in rats and promotes hepatic FAO in mice. Therefore,...
Source: Toxicology Letters - April 17, 2024 Category: Toxicology Authors: Hitoshi Nakamura Toshikatsu Matsui Tadahiro Shinozawa Source Type: research

Association between Per- and poly-fluoroalkyl substances and nonalcoholic fatty liver disease: a nested case-control study in northwest China
In conclusion, our findings suggest that individual and co-exposure to PFAS is associated with a risk of NAFLD onset.PMID:38631453 | DOI:10.1016/j.envpol.2024.123937 (Source: Environmental Pollution)
Source: Environmental Pollution - April 17, 2024 Category: Environmental Health Authors: Yuanqin Wu Zhiyuan Cheng Wei Zhang Chun Yin Jianyun Sun Honghao Hua Xianzhen Long Xijiang Wu Yufeng Wang Xiaoyu Ren Desheng Zhang Yana Bai Yongjun Li Ning Cheng Source Type: research

From the Editor ’s Desk...
Metabolic dysfunction-associated steatotic liver disease (MASLD) has replaced non-alcoholic fatty liver disease (NAFLD). However, given that MASLD requires at least one cardiometabolic risk factor, questions were raised as to whether new evidence would need to be generated for MASLD. In this issue, Younossi and coworkers compared the clinical profile and outcomes of NAFLD to MASLD using a tertiary-care NAFLD database and NHANES-III. Ninety-nine percent of included patients met MASLD criteria while 95% met MASLD criteria on BMI only. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 17, 2024 Category: Gastroenterology Authors: Patrizia Burra, Frank Tacke, Vlad Ratziu, Stefan Zeuzem, Bruno Sangro, Paolo Angeli Tags: From the Editor's Desk Source Type: research

Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment
ConclusionThe present GL is directed to all physicians addressing people with obesity —working in hospitals, territorial services or private practice—and to general practitioners and patients. The recommendations should also consider the patient’s preferences and the available resources and expertise. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - April 17, 2024 Category: Endocrinology Source Type: research

Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against non-alcoholic fatty liver disease
CONCLUSIONS: Ursolic acid could improve immune inflammation in NAFLD by modulating SPP1-mediated Th17 cell differentiation via the ERK signaling pathway, which is orchestrated jointly by ITGB1 and CD44, emerging as a linchpin in this molecular cascade.PMID:38623614 | DOI:10.3350/cmh.2024.0047 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - April 16, 2024 Category: Gastroenterology Authors: Yiyuan Zheng Lina Zhao Zhekun Xiong Chaoyuan Huang Qiuhong Yong Dan Fang Yugang Fu Simin Gu Chong Chen Jiacheng Li Yingying Zhu Jing Liu Fengbin Liu Yong Li Source Type: research

Cancers, Vol. 16, Pages 1513: Time-Restricted Feeding Attenuates Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma in Obese Male Mice
In this study, we tested a time-restricted feeding (TRF) nutritional intervention in mouse models of MASH and HCC. We show that TRF abrogated metabolic dysregulation induced by a Western diet without any calorie restriction or weight loss. TRF improved insulin sensitivity and reduced hyperinsulinemia, liver steatosis, inflammation, and fibrosis. Importantly, TRF inhibited liver tumors in two mouse models of obesity-driven HCC. Our data suggest that TRF is likely to be effective in abrogating MASH and HCC and warrant further studies of time-restricted eating in humans with MASH who are at higher risk of developing HCC. (Source: Cancers)
Source: Cancers - April 16, 2024 Category: Cancer & Oncology Authors: Manasi Das Deepak Kumar Consuelo Sauceda Alexis Oberg Lesley G. Ellies Liping Zeng Lily J. Jih Isabel G. Newton Nicholas J. G. Webster Tags: Article Source Type: research

Incretin-based investigational therapies for the treatment of MASLD/MASH
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common form of chronic liver disease. It exists as either simple steatosis or its more progressive form, metabolic dysfunction-associated steatohepatitis (MASH), formerly, non-alcoholic steatohepatitis (NASH). The global prevalence of MASLD is estimated to be 32% among adults and is projected to continue to rise with increasing rates of obesity, type 2 diabetes, and metabolic syndrome. (Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - April 16, 2024 Category: Endocrinology Authors: Bram Brouwers, Girish Rao, Yuanyuan Tang, Ángel Rodríguez, Leonard C Glass, Mark L Hartman Source Type: research

Alpha lipoic acid administration improved both peripheral sensitivity to insulin and liver clearance of insulin reducing potential risk of diabetes and nonalcoholic fatty liver disease in overweight/obese PCOS patients
Volume 40, Issue 1, December 2024 . (Source: Gynecological Endocrinology)
Source: Gynecological Endocrinology - April 16, 2024 Category: Endocrinology Authors: Alessandro D. GenazzaniChristian BattipagliaLaura RusceGreta PrampoliniClaudia AioFrancesco RicciardielloMartina FoschiAlessandra SponzilliElisa SempriniTabatha PetrilloGynecological Endocrinology Center, Department of Obstetrics and Gynecology, Universit Source Type: research

Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation
ConclusionsThe quantitative measurement system for M2BPGi depends on liver fibrosis and inflammation, regardless of etiology. Liver inflammation complicates the interpretation of M2BPGi-Qt results when assessing the fibrosis stage. (Source: Journal of Gastroenterology)
Source: Journal of Gastroenterology - April 16, 2024 Category: Gastroenterology Source Type: research

Bioprotective Role of Phytocompounds Against the Pathogenesis of Non-alcoholic Fatty Liver Disease to Non-alcoholic Steatohepatitis: Unravelling Underlying Molecular Mechanisms
Planta Med DOI: 10.1055/a-2277-4805Non-alcoholic fatty liver disease (NAFLD), with a global prevalence of 25%, continues to escalate, creating noteworthy concerns towards the global health burden. NAFLD causes triglycerides and free fatty acids to build up in the liver. The excessive fat build-up causes inflammation and damages the healthy hepatocytes, leading to non-alcoholic steatohepatitis (NASH). Dietary habits, obesity, insulin resistance, type 2 diabetes, and dyslipidemia influence NAFLD progression. The disease burden is complicated due to the paucity of therapeutic interventions. Obeticholic acid is the only approv...
Source: Planta Medica - April 15, 2024 Category: Drugs & Pharmacology Authors: Banerjee, Tanmoy Sarkar, Arnab Ali, Sk Zeeshan Bhowmik, Rudranil Karmakar, Sanmoy Halder, Amit Kumar Ghosh, Nilanjan Tags: Reviews Source Type: research

Metabolic Syndrome and Cardiac Vessel Remodeling Associated with Vessel Rarefaction: A Possible Underlying Mechanism May Result from a Poor Angiogenic Response to Altered VEGF Signaling Pathways
J Vasc Res. 2024 Apr 12:1-9. doi: 10.1159/000538361. Online ahead of print.ABSTRACTBACKGROUND: Elevated mortality rates in patients with metabolic syndrome (MetS) are partly due to adverse remodeling of multiple organs, which may lead to cardiovascular disease, nonalcoholic fatty liver disease, kidney failure, or other conditions. MetS symptoms, such as obesity, hypertension, hyperglycemia, dyslipidemia, associated with insulin and leptin resistance, are recognized as major cardiovascular risk factors that adversely affect the heart.SUMMARY: Pathological cardiac remodeling is accompanied by endothelial cell dysfunction whi...
Source: Cell Research - April 14, 2024 Category: Cytology Authors: Krzysztof Bartkowiak Mateusz Bartkowiak Ewa Jankowska-Steifer Anna Ratajska Marek Kujawa Olga Anio łek Justyna Niderla-Bieli ńska Source Type: research